JP2014530246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530246A5 JP2014530246A5 JP2014536225A JP2014536225A JP2014530246A5 JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5 JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014536225 A JP2014536225 A JP 2014536225A JP 2014530246 A5 JP2014530246 A5 JP 2014530246A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- sulfated glycosaminoglycan
- administered
- dose
- sulfated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010054218 Factor VIII Proteins 0.000 claims 23
- 102000001690 Factor VIII Human genes 0.000 claims 23
- 229960000301 factor viii Drugs 0.000 claims 23
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 21
- 230000037396 body weight Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 208000031169 hemorrhagic disease Diseases 0.000 claims 4
- 229920000669 heparin Polymers 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000010253 intravenous injection Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548606P | 2011-10-18 | 2011-10-18 | |
| EP11185648 | 2011-10-18 | ||
| EP11185648.0 | 2011-10-18 | ||
| US61/548,606 | 2011-10-18 | ||
| PCT/EP2012/070615 WO2013057167A1 (en) | 2011-10-18 | 2012-10-18 | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530246A JP2014530246A (ja) | 2014-11-17 |
| JP2014530246A5 true JP2014530246A5 (OSRAM) | 2015-11-26 |
| JP6072810B2 JP6072810B2 (ja) | 2017-02-01 |
Family
ID=48140372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536225A Expired - Fee Related JP6072810B2 (ja) | 2011-10-18 | 2012-10-18 | 第ｖｉｉｉ因子の生物学的利用能を改善するための硫酸化グリコサミノグリカンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9393289B2 (OSRAM) |
| EP (1) | EP2768522B1 (OSRAM) |
| JP (1) | JP6072810B2 (OSRAM) |
| KR (1) | KR20140083036A (OSRAM) |
| CN (1) | CN103889445A (OSRAM) |
| AU (1) | AU2012318279B2 (OSRAM) |
| CA (1) | CA2852397A1 (OSRAM) |
| DK (1) | DK2768522T3 (OSRAM) |
| ES (1) | ES2600081T3 (OSRAM) |
| WO (1) | WO2013057167A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511123B2 (en) | 2011-10-18 | 2016-12-06 | Csl Behring Gmbh | Combined use of a sulfated glycosaminoglycan and a hyaluronidase for improving the bioavailability of factor VIII |
| JP6605593B2 (ja) | 2014-06-06 | 2019-11-13 | オクタファルマ・アーゲー | 第ｖｉｉｉ因子およびフォン・ヴィルブランド因子ペプチドを含む製剤 |
| EP3191524A4 (en) * | 2014-09-12 | 2018-05-30 | The Regents of The University of California | Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics |
| KR102698387B1 (ko) * | 2015-02-06 | 2024-08-22 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 |
| SE539575C2 (en) * | 2015-07-30 | 2017-10-17 | Tx Medic Ab | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| JPH0788399B2 (ja) | 1985-04-12 | 1995-09-27 | ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド | 新規プロコアギュラント蛋白質 |
| FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| DE69735421T2 (de) | 1996-04-24 | 2006-10-19 | The Regents Of The University Of Michigan, Ann Arbor | Gegen inaktivierung resistenter faktor viii |
| AU1598200A (en) | 1998-10-23 | 2000-05-15 | Trustees Of The University Of Pennsylvania, The | Systemic delivery of gene products via skin |
| US20040192599A1 (en) | 2001-06-15 | 2004-09-30 | Schuh Andre C | Gene therapy for hemophilia a |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| DE602004031390D1 (de) | 2003-05-06 | 2011-03-24 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten |
| BRPI0820271A2 (pt) * | 2007-11-09 | 2015-05-26 | Baxter Int | Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada. |
| ES2476690T3 (es) * | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| CA2770609A1 (en) | 2009-08-20 | 2011-02-24 | Csl Behring Gmbh | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| WO2011095604A1 (en) * | 2010-02-04 | 2011-08-11 | Octapharma Biopharmaceuticals Gmbh | Half-life prolongation of proteins |
-
2012
- 2012-10-18 DK DK12777895.9T patent/DK2768522T3/en active
- 2012-10-18 JP JP2014536225A patent/JP6072810B2/ja not_active Expired - Fee Related
- 2012-10-18 CN CN201280051236.7A patent/CN103889445A/zh active Pending
- 2012-10-18 WO PCT/EP2012/070615 patent/WO2013057167A1/en not_active Ceased
- 2012-10-18 KR KR1020147013300A patent/KR20140083036A/ko not_active Withdrawn
- 2012-10-18 CA CA2852397A patent/CA2852397A1/en not_active Abandoned
- 2012-10-18 US US14/352,540 patent/US9393289B2/en not_active Expired - Fee Related
- 2012-10-18 AU AU2012318279A patent/AU2012318279B2/en not_active Ceased
- 2012-10-18 ES ES12777895.9T patent/ES2600081T3/es active Active
- 2012-10-18 EP EP12777895.9A patent/EP2768522B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| AR082150A1 (es) | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolin-3-carboxamida deuterada, sales y usos de la misma, metodo de tratamiento, mezcla compuestos, composicion farmaceutica, proceso de preparacion, compuesto enriquecido con deuterio | |
| MX2022007012A (es) | Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico. | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2016517421A5 (OSRAM) | ||
| MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
| NZ747657A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JP2016508123A5 (OSRAM) | ||
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| JP2014530246A5 (OSRAM) | ||
| MX2013014543A (es) | Tratamiento de trastornos de la coagulacion mediante la administracion del factor von willebrand (vwf) recombinante. | |
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| JP2014530873A5 (OSRAM) | ||
| MX2009010268A (es) | Reduccion de eventos adversos despues de intervencion percutanea mediante el uso de un antagonista del receptor de trombina. | |
| PH12015501373A1 (en) | Injectable depot formulation comprising optically active tolvaptan and process of producing the same | |
| PH12015502465A1 (en) | Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias | |
| RU2013108390A (ru) | Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека | |
| JP2013520447A5 (OSRAM) | ||
| FI3648788T5 (fi) | Maha-suolikanavan verenvuodon hoito vaikeaa von willebrandin tautia sairastavilla potilailla antamalla rekombinanttia vwf:ää | |
| FI3590960T3 (fi) | Perifeeristen hermojen IgG-stimuloitu remyelinaatio | |
| WO2019094823A8 (en) | Mitochondrial localization signals in human tafazzin and uses thereof | |
| MY163107A (en) | Pharmaceutical composition for the treatment of bladder disorders | |
| MX2018013474A (es) | Acidos carboxilicos para aplicacion en la primera infancia. | |
| Marzuillo et al. | Ondasetron Is More Likely Than Ketamine to Cause Ventricular Tachycardia | |
| AT511582B1 (de) | Verwendung von keyhole-limpet-hämocyanin oder spaltprodukten davon |